Effectiveness of idarubicin-intensified myeloablastive conditioning regimen in allogeneic peripheral blood stem cell transplantation in 12 patients with myelodysplastic syndromes
10.3760/cma.j.issn.0254-1785.2010.02.005
- VernacularTitle:增强预处理方案的造血干细胞移植对骨髓增生异常综合征的治疗效果
- Author:
Yin XIAO
;
Yong YOU
;
Zhichao CHEN
;
Linghui XIA
;
Mei HONG
;
Ping ZOU
- Publication Type:Journal Article
- Keywords:
Transplantation conditioning;
Hematopoietic stem cell transplantation;
Myelodysplastic syndromes
- From:
Chinese Journal of Organ Transplantation
2010;31(2):75-78
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the outcome of idarubicin-intensified myeloablastive conditioning regimen in allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in patients with myelodysplastic syndromes (MDS). Methods From August 2004 to July 2009, 12 patients with MDS were treated with alIo-PBSCT following the idarubicin-intensified conditioning regimen. The conditioning regimen was idarubicin (15 mg/m~2), continuous intravenous infusion for 20 h, days-12 to-10; busulfan (0.8 mg/kg), intravenous infusion every 6 h, days-6 to-4; cyclophosphamide (1.8 g/m~2), intravenous infusion every 6 h, days-3 to-2; cyclosporine A combined with short-term methotrexate was used for the prophylaxes of acute graft versus host disease (aGVHD). Results All twelve patients achieved Trilineage engraftment, and were well tolerated to this regimen. Eight patients survived, and the overall survival was 66.7%, disease-free survival (DFS) 58.3%. Two patients relapsed. OS for neither WHO subgroups nor IPSS subgroups had statistically significant difference. Conclusion Allo-PBSCT with idarubicin-inteusified conditioning regimen is an effective treatment with reduction of the relapse rate for MDS patients.
